Phase I Clinical Trial of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia
Status:
COMPLETED
Trial end date:
2024-06-02
Target enrollment:
Participant gender:
Summary
This study is testing CG2001, a new medicine that is applied as a light foam to the scalp and is being developed to treat male-pattern hair loss (androgenetic alopecia). The main goals are to find out:
1. Whether single and repeated daily doses of CG2001 are safe and well-tolerated
2. How much of the drug, if any, enters the bloodstream (pharmacokinetics)